DEF 14A: Allogene Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Allogene Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals for director elections, executive compensation advisory vote, and ratification of the independent accounting firm.

Summary

• Allogene Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, at 8:00 a.m. Pacific Time.
• Stockholders of record as of April 22, 2025, are eligible to vote.
• The meeting will address the election of three Class I directors (Elizabeth Barrett, Arie Belldegrun, and David Chang) for terms expiring in 2028.
• An advisory vote on executive compensation will be conducted.
• The ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, will be voted on.
• The board recommends voting 'For' all nominees and proposals.
• The company highlights its commitment to good corporate governance and provides details on board independence, committee structures, and ESG practices.
• The company's Board of Directors consists of eleven members, with six being diverse by gender or race.
• The company's Corporate Governance Guidelines were adopted in September 2024.
• The company's Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information for the annual meeting. The company highlights its commitment to good governance and responsiveness to stockholder feedback, which is moderately positive.

Positives

• The company is committed to good corporate governance, with a majority of independent directors.
• The company has adopted Corporate Governance Guidelines to support effective execution of fiduciary duties.
• The company has a robust stockholder engagement program.
• The company has a Code of Business Conduct and Ethics that applies to all officers, directors, and employees.
• The company has a clawback policy for incentive compensation.

Negatives

• The company maintains a classified board structure, which some investors may view negatively.
• The company's Executive Chair is deemed non-independent due to a consulting relationship with the company.
• The company's former contractual relationship with Two River, terminated in December 2023, resulted in one director being deemed non-independent.

Risks

• The company operates in a highly competitive and regulated industry.
• The company's success depends on the specialized skills, talent, and dedication of its executive officers.
• The company's forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those projected.
• The company's reliance on third parties for manufacturing and supply of its product candidates.
• The company's dependence on the success of its clinical trials.

Future Outlook

The company anticipates potential commercialization of its product candidates as early as 2027.

Management Comments

• The Board of Directors believes that a classified board remains appropriate at this time.
• The Board of Directors recognizes ongoing stockholder interest in board declassification and the benefits of annual director elections.
• The Board will actively consider proposing a phased board declassification when these protections are no longer deemed appropriate to safeguard stockholder interests.

Industry Context

The company operates in the competitive biotechnology industry, focusing on allogeneic CAR T cell therapies for cancer and autoimmune diseases.

Comparison to Industry Standards

• The company benchmarks its executive compensation program against a peer group of publicly-traded biotechnology and pharmaceutical companies.
• The company's peer group includes Agios Pharmaceuticals, Fate Therapeutics, Mirati Therapeutics, and others.
• The company's executive chair compensation is set at approximately the 50th percentile of comparable companies with executive chairs having expanded roles.
• The company's classified board structure is common among its peers, with 80% having a classified board structure.

Corporate Governance

Related Party Transactions

• The company maintains a consulting agreement with Bellco Capital LLC, owned by the Executive Chair, Arie Belldegrun.
• The company previously maintained a consulting agreement with Two River, LLC, of which Arie Belldegrun and Joshua Kazam are partners and David Chang is a venture partner (agreement terminated in December 2023).
• The company has a sublease agreement with Bellco for office space in Los Angeles.

Stakeholder Impact

• The company's actions and decisions impact stockholders, employees, customers, suppliers, and creditors.
• The company is committed to responsible and sustainable business practices, aligning its ESG initiatives with its core mission and long-term strategic objectives.
• The company is committed to cultivating a workplace environment characterized by belonging, fairness, and representation.

Next Steps

• Stockholders are encouraged to vote on the proposals.
• The Board and management intend to continue annual reviews of the classified board structure, voting standards, compensation and equity programs.
• The company will continue to engage with stockholders on governance and executive compensation matters.

Key Dates

Keywords

proxy statement, annual meeting, corporate governance, executive compensation, board of directors, Allogene Therapeutics, directors, stockholders, audit committee, independent registered public accounting firm